Abstract
The sharp increase of COVID-19 cases in late 2020 has made Brazil the new epicenter of the ongoing SARS-CoV-2 pandemic. Novel SARS-CoV-2 lineages P.1 and P.2, first identified respectively in Manaus and Rio de Janeiro, have been associated with potentially higher transmission rates and antibody neutralization escape. In this study, we performed a whole-genome sequencing of 185 samples isolated from three out of the five Brazilian regions, including Amazonas (North region), Rio Grande do Norte, Paraíba and Bahia (Northeast region), and Rio de Janeiro (Southeast region) aiming to identify SARS-CoV-2 mutations that could be involved in the surge of COVID19 cases in Brazil. Here, we showed a widespread dispersion of P.1 and P.2 across Brazilian regions. Except for Manaus, P.2 was the predominant lineage identified country-wise. P.2 lineage was estimated to have originated in February, 2020 and has diverged into new clades. Interstate transmission of P.2 was detected since March, but reached its peak in December, 2020 and January, 2021. Transmission of P.1 was also high in December. P.1 origin was inferred to have happened in August 2020. We also confirmed the presence of the variant under investigation (VUI) NP13L, recently described in the southernmost region of Brazil, to have spread across the Northeastern states. P.1, P.2 and NP13L are descended from the ancient B.1.1.28 strain, although during the first phase of the pandemic in Brazil presence of B.1.1.33 strain was also reported. We investigate here the possible occurrence of a new variant of interest descending from B.1.1.33 that also carries the E484K mutation. Indeed, the recurrent report of many novel SARS-CoV-2 genetic variants in Brazil could be due to the absence of effective control measures resulting in high SARS-CoV2 transmission rates. Altogether, our findings provided a landscape of the critical state of SARS-CoV-2 across Brazil and confirm the need to sustain continuous sequencing of the SARS-CoV-2 isolates worldwide in order to early identify novel variants of interest and to monitor for vaccine effectiveness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was developed in the frameworks of Coronaomica RJ (FAPERJ = E-26/210.179/2020) and Rede Coronaomica BR MCTI/FINEP (FINEP = 01.20.0029.000462/20, CNPq = 404096/2020.4). A.T.R.V is supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico CNPq (303170/2017.4) and FAPERJ (E-26/202.903/20). R.S.F.J is a recipient of a graduate fellowship from CNPq. A.P.L is granted a post-doctoral scholarship (DTI.A) from CNPq. SMBJ was supported by Ministerio da Educacao (UFRN Covid Task Force), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (440893/2016.0) and by JBS. E.S.S.S was supported by Fundacao de Amparo a Pesquisa do Estado da Paraiba FAPESQ (003/2020) and Laboratorios de Campanha MCTI/FINEP (0494/20 01.20.0026.00). L.F.A.L was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The present study was approved by Ethical Review Board/Brazilian Commission of Ethical Study (Research Ethics Committee of: Universidade Federal Rio Grande do Norte - CAAE 36287120.2.0000.5537, CAAE 32049320.3.0000.5537, Universidade Federal da Paraiba - CAAE 30658920.4.3004.5183, Universidade Estadual do Rio de Janeiro - CAAE 30135320.0.0000.5259 and Universidade Estadual de Santa Cruz - CAAE 39142720.5.0000.5526). All data was analyzed anonymously.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All sequence data is available in GISAID database. Accession numbers are located in Table S1.
